DNA-PKcs

Function

DNA-PKcs is the catalytic subunit of a nuclear DNA-dependent serine/threonine protein kinase called DNA-PK. The second component is the autoimmune antigen Ku. On its own, DNA-PKcs is inactive and relies on Ku to direct it to DNA ends and trigger its kinase activity. DNA-PKcs is required for the non-homologous end joining (NHEJ) pathway of DNA repair, which rejoins double-strand breaks. It is also required for V(D)J recombination, a process that utilizes NHEJ to promote immune system diversity.

Many proteins have been identified as substrates for the kinase activity of DNA-PK. Autophosphorylation of DNA-PKcs appears to play a key role in NHEJ and is thought to induce a conformational change that allows end processing enzymes to access the ends of the double-strand break. DNA-PK also cooperates with ATR and ATM to phosphorylate proteins involved in the DNA damage checkpoint.

Disease

DNA-PKcs knockout mice have severe combined immunodeficiency due to their V(D)J recombination defect. Natural analogs of this knockout happen in mice, horses and dogs, also causing SCID. Human SCID usually have other causes, but two cases related to mutations in this gene are also known.

Apoptosis

DNA-PKcs activates p53 to regulate apoptosis. In response to ionizing radiation, DNA-PKcs can serve as an upstream effector for p53 protein activation, thus linking DNA damage to apoptosis. The replication of DNA in such deficient cells can generate mutations and such mutations may cause cancer. Thus DNA-PKcs appears to have two functions related to the prevention of cancer, where the first function is to participate in the repair of DNA double-strand breaks by the NHEJ repair pathway and the second function is to induce apoptosis if the level of such DNA breaks exceed the cell's repair capability

Cancer

DNA damage appears to be the primary underlying cause of cancer, and deficiencies in DNA repair genes likely underlie many forms of cancer. If DNA repair is deficient, DNA damage tends to accumulate. Such excess DNA damage may increase mutations due to error-prone translesion synthesis. Excess DNA damage may also increase epigenetic alterations due to errors during DNA repair. Such mutations and epigenetic alterations may give rise to cancer.

PRKDC (DNA-PKcs) mutations were found in 3 out of 10 of endometriosis-associated ovarian cancers, as well as in the field defects from which they arose. They were also found in 10% of breast and pancreatic cancers.

Reductions in expression of DNA repair genes (usually caused by epigenetic alterations) are very common in cancers, and are ordinarily even more frequent than mutational defects in DNA repair genes in cancers. DNA-PKcs expression was reduced by 23% to 57% in six cancers as indicated in the table.

It is not clear what causes reduced expression of DNA-PKcs in cancers. MicroRNA-101 targets DNA-PKcs via binding to the 3'- UTR of DNA-PKcs mRNA and efficiently reduces protein levels of DNA-PKcs. But miR-101 is more often decreased in cancers, rather than increased.

HMGA2 protein could also have an effect on DNA-PKcs. HMGA2 delays the release of DNA-PKcs from sites of double-strand breaks, interfering with DNA repair by non-homologous end joining and causing chromosomal aberrations. The let-7a microRNA normally represses the HMGA2 gene. In normal adult tissues, almost no HMGA2 protein is present. In many cancers, let-7 microRNA is repressed. As an example, in breast cancers the promoter region controlling let-7a-3/let-7b microRNA is frequently repressed by hypermethylation. Epigenetic reduction or absence of let-7a microRNA allows high expression of the HMGA2 protein and this would lead to defective expression of DNA-PKcs.

DNA-PKcs can be up-regulated by stressful conditions such as in Helicobacter pylori-associated gastritis. After ionizing radiation DNA-PKcs was increased in the surviving cells of oral squamous cell carcinoma tissues.

The ATM protein is important in homologous recombinational repair (HRR) of DNA double strand breaks. When cancer cells are deficient in ATM the cells are "addicted" to DNA-PKcs, important in the alternative DNA repair pathway for double-strand breaks, non-homologous end joining (NHEJ). That is, in ATM-mutant cells, an inhibitor of DNA-PKcs causes high levels of apoptotic cell death. In ATM mutant cells, additional loss of DNA-PKcs leaves the cells without either major pathway (HRR and NHEJ) for repair of DNA double-strand breaks.

Elevated DNA-PKcs expression is found in a large fraction (40% to 90%) of some cancers (the remaining fraction of cancers often has reduced or absent expression of DNA-PKcs). The elevation of DNA-PKcs is thought to reflect the induction of a compensatory DNA repair capability, due to the genome instability in these cancers. (As indicated in the article Genome instability, such genome instability may be due to deficiencies in other DNA repair genes present in the cancers.) Elevated DNA-PKcs is thought to be "beneficial to the tumor cells", though it would be at the expense of the patient. As indicated in a table listing 12 types of cancer reported in 20 publications, the fraction of cancers with over-expression of DNA-PKcs is often associated with an advanced stage of the cancer and shorter survival time for the patient. However, the table also indicates that for some cancers, the fraction of cancers with reduced or absent DNA-PKcs is also associated with advanced stage and poor patient survival.

Aging

Non-homologous end joining (NHEJ) is the principal DNA repair process used by mammalian somatic cells to cope with double-strand breaks that continually occur in the genome. DNA-PKcs is one of the key components of the NHEJ machinery. DNA-PKcs deficient mice have a shorter lifespan and show an earlier onset of numerous aging related pathologies than corresponding wild-type littermates. These findings suggest that failure to efficiently repair DNA double-strand breaks results in premature aging, consistent with the DNA damage theory of aging. (See also Bernstein et al.)

Interactions

DNA-PKcs has been shown to interact with:

• ATM,
• C1D, and
• CDC5L,
• CHEK1,
• CHUK,
• CIB1,
• DCLRE1C,
• ILF2,
• ILF3,
• Ku80,
• NCOA6,
• P53,
• RPA2, and
• WRN.

DNA-PKcs Inhibitors

AZD7648, M3814 (peposertib), M9831 (VX-984) and BAY-8400 have been described as potent and selective DNA-PKcs inhibitors.

References

References

1. (2023). "Lost in the bloom: DNA-PKcs in green plants". Front Plant Sci.
2. (August 1995). "Gene for the catalytic subunit of the human DNA-activated protein kinase maps to the site of the XRCC7 gene on chromosome 8". Proceedings of the National Academy of Sciences of the United States of America.
3. (January 2010). "Crystal structure of DNA-PKcs reveals a large open-ring cradle {{sic". Nature.
4. (September 1995). "DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product". Cell.
5. "Entrez Gene: PRKDC protein kinase, DNA-activated, catalytic polypeptide".
6. (2008). "Chapter 2 DNA-PK".
7. (August 2009). "SCID dogs: similar transplant potential but distinct intra-uterine growth defects and premature replicative senescence compared with SCID mice". Journal of Immunology.
8. (April 2020). "DNA-PKcs chemical inhibition versus genetic mutation: Impact on the junctional repair steps of V(D)J recombination". Molecular Immunology.
9. (February 2000). "The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest". Proc Natl Acad Sci U S A.
10. (June 2002). "DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis". Mutat Res.
11. (April 2008). "DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture". Molecular Cancer Research.
12. (December 2007). "The DNA damage response: ten years after". Molecular Cell.
13. (December 2014). "Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy". Clinical Cancer Research.
14. (August 2008). "Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island". PLOS Genetics.
15. (July 2007). "DNA damage, homology-directed repair, and DNA methylation". PLOS Genetics.
16. (July 2016). "Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer". Journal of Molecular Medicine.
17. (February 2008). "Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers". Cancer Research.
18. (December 2010). "Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer". International Journal of Oncology.
19. (December 2012). "DNA-PKcs expression predicts response to radiotherapy in prostate cancer". International Journal of Radiation Oncology, Biology, Physics.
20. (July 2007). "[Potentials of DNA-PKcs, Ku80, and ATM in enhancing radiosensitivity of cervical carcinoma cells]". AI Zheng = Aizheng = Chinese Journal of Cancer.
21. (August 2005). "Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma". International Journal of Radiation Oncology, Biology, Physics.
22. (December 2014). "ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers". BBA Clinical.
23. (April 2005). "Loss of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in gastric cancers". Cancer Research and Treatment.
24. (July 2010). "Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation". PLOS ONE.
25. (August 2015). "MicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8". Journal of Translational Medicine.
26. (January 2016). "MicroRNA-101 suppresses migration and invasion via targeting vascular endothelial growth factor-C in hepatocellular carcinoma cells". Oncology Letters.
27. (July 2009). "Suppression of nonhomologous end joining repair by overexpression of HMGA2". Cancer Research.
28. (April 2008). "Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family". Clinical Cancer Research.
29. (March 2015). "Let-7a inhibits migration, invasion and epithelial-mesenchymal transition by targeting HMGA2 in nasopharyngeal carcinoma". Journal of Translational Medicine.
30. (2013). "miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer". PLOS ONE.
31. (October 2007). "Altered expression of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) during gastric carcinogenesis and its clinical implications on gastric cancer". International Journal of Oncology.
32. (October 2003). "Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma". Cancer Science.
33. (June 2013). "Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors". Science Translational Medicine.
34. (June 2012). "Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment". Translational Cancer Research.
35. (May 2004). "Shorter telomeres, accelerated ageing and increased lymphoma in DNA-PKcs-deficient mice". EMBO Reports.
36. (2014). "The progeroid phenotype of Ku80 deficiency is dominant over DNA-PKCS deficiency". PLOS ONE.
37. (2008). "New Research on DNA Damages". [[Nova Science Publishers, Inc..
38. (September 1999). "Recruitment of ATM protein to double strand DNA irradiated with ionizing radiation". The Journal of Biological Chemistry.
39. (December 2000). "Functional analysis of the human CDC5L complex and identification of its components by mass spectrometry". The EMBO Journal.
40. (December 1999). "Substrate specificities and identification of putative substrates of ATM kinase family members". The Journal of Biological Chemistry.
41. (August 2003). "Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex". The Journal of Biological Chemistry.
42. (July 1998). "DNA-dependent protein kinase phosphorylation of IkappaB alpha and IkappaB beta regulates NF-kappaB DNA binding properties". Molecular and Cellular Biology.
43. (October 1997). "Interaction between DNA-dependent protein kinase and a novel protein, KIP". Mutation Research.
44. (March 2002). "Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination". Cell.
45. (January 1998). "DNA-dependent protein kinase interacts with antigen receptor response element binding proteins NF90 and NF45". The Journal of Biological Chemistry.
46. (October 1997). "Binding of Ku and c-Abl at the kinase homology region of DNA-dependent protein kinase catalytic subunit". The Journal of Biological Chemistry.
47. (October 2002). "Ku antigen, an origin-specific binding protein that associates with replication proteins, is required for mammalian DNA replication". Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression.
48. (September 1999). "Mapping of protein-protein interactions within the DNA-dependent protein kinase complex". Nucleic Acids Research.
49. (May 2000). "Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator". Proceedings of the National Academy of Sciences of the United States of America.
50. (March 1999). "Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes". The EMBO Journal.
51. (April 2020). "The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor". Journal of Medicinal Chemistry.
52. (2020). "Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models". Molecular Cancer Therapeutics.
53. (May 2018). "VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells". Oncotarget.
54. (September 2021). "BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies". Journal of Medicinal Chemistry.